Available 24/7 for Urgent On-Site or Virtual Consulting

FDA Inspections

Consulting and Compliance

Day: September 25, 2025

Inspections

How COVID Changed Remote FDA Inspections—and What It Means for 2025
ByFDA Inspections Team September 25, 2025September 25, 2025

The COVID-19 pandemic acted as a catalyst, forcing the FDA to rapidly adapt its traditional on-site inspection methods. This shift gave rise to Remote Interactive Evaluations (RIEs) and other virtual oversight tools, fundamentally altering the regulatory landscape. This article explores the lasting remote FDA inspections COVID impact, detailing the transition from physical to virtual audits, the key technologies involved, and the new compliance challenges companies face as we head into 2025.

Read More How COVID Changed Remote FDA Inspections—and What It Means for 2025
Warning Letters

How to Respond to an FDA Warning Letter: Strategy, Timing & Tone
ByFDA Inspections Team September 25, 2025September 25, 2025

Receiving an FDA warning letter is a critical event for any regulated company. It signals significant regulatory violations that require immediate and thorough attention. A poorly crafted response can escalate the situation, leading to severe penalties. This guide provides a comprehensive strategy on how to respond to an FDA warning letter, covering everything from the initial assessment and team assembly to the critical 15-day deadline, drafting a detailed response, and implementing effective corrective actions.

Read More How to Respond to an FDA Warning Letter: Strategy, Timing & Tone
Inspections

Building an FDA Inspection Readiness Plan: Steps for a Compliant Facility
ByFDA Inspections Team September 25, 2025September 25, 2025

Prepare your facility for scrutiny with a comprehensive FDA inspection readiness plan. This guide outlines the essential steps, from assembling a dedicated readiness team and conducting rigorous mock inspections to mastering document control and training your staff. Learn how to proactively identify and address potential compliance gaps, manage logistics for the inspection day, and handle post-inspection communications effectively. A solid plan minimizes stress and prevents costly regulatory actions.

Read More Building an FDA Inspection Readiness Plan: Steps for a Compliant Facility
Inspections

Part 11 Software Validation Checklist: Ensure Compliance from Day One
ByFDA Inspections Team September 25, 2025September 25, 2025

In the life sciences industry, data integrity is paramount. FDA’s 21 CFR Part 11 sets the standard for electronic records and signatures, making software validation a non-negotiable activity. Failing to comply can lead to significant regulatory actions, including Form 483s and Warning Letters. This guide provides a comprehensive part 11 software validation checklist to help you navigate the complexities of compliance, ensuring your systems are secure, reliable, and inspection-ready from day one.

Read More Part 11 Software Validation Checklist: Ensure Compliance from Day One
Inspections

GxP Compliance in Virtual Laboratories: Key Challenges and Best Practices
ByFDA Inspections Team September 25, 2025September 25, 2025

The shift to virtual laboratories presents immense opportunities for innovation in the life sciences industry, but it also introduces complex regulatory challenges. Achieving GxP compliance for virtual laboratories is critical for ensuring product quality, safety, and efficacy. This comprehensive guide explores the primary hurdles, such as ensuring data integrity, validating cloud-based software, and managing remote teams, that companies face. More importantly, it outlines actionable best practices and robust strategies to build a compliant digital framework from the ground up, helping you avoid common pitfalls that can lead to severe regulatory actions. By understanding these dynamics, you can harness the power of virtual environments while upholding the highest standards of quality and compliance.

Read More GxP Compliance in Virtual Laboratories: Key Challenges and Best Practices
Inspections

Using AI in Pharmaceutical Quality Control: Opportunities & Compliance Risks
ByFDA Inspections Team September 25, 2025September 25, 2025

The integration of Artificial Intelligence (AI) is revolutionizing pharmaceutical quality control, offering unprecedented efficiency and accuracy. From predictive maintenance to real-time process monitoring, AI promises to reduce human error and enhance product consistency. However, this powerful technology also introduces significant compliance challenges. Navigating data integrity, model validation, and evolving regulatory expectations is crucial to avoid serious FDA actions. This article explores the key opportunities and compliance risks associated with AI in pharmaceutical quality control, guiding companies on how to innovate responsibly while upholding the highest standards of safety and quality in a regulated environment.

Read More Using AI in Pharmaceutical Quality Control: Opportunities & Compliance Risks
Warning Letters

Top Reasons Medical Device Companies Receive FDA Warning Letters
ByFDA Inspections Team September 25, 2025September 25, 2025

Receiving an FDA warning letter can severely impact a medical device company’s operations, reputation, and financial stability. These letters signify serious regulatory violations that were not adequately addressed after an inspection. Understanding the common pitfalls is the first step toward building a robust compliance framework. This article explores the top reasons medical device companies receive warning letters, from inadequate CAPA systems and poor complaint handling to failures in design and process controls. Learn how to strengthen your quality system and maintain a constant state of inspection readiness.

Read More Top Reasons Medical Device Companies Receive FDA Warning Letters
Inspections

A Practical Guide to GMP Compliance for OTC Pharmaceutical Manufacturers
ByFDA Inspections Team September 25, 2025September 25, 2025

This definitive guide provides a practical roadmap to achieving and maintaining GMP compliance for OTC pharmaceutical manufacturers. We delve deep into the core tenets of 21 CFR Part 211, from establishing a robust Quality Management System to navigating personnel training, facility management, and meticulous documentation. Learn how to prepare for FDA inspections, avoid common 483 observations, and build a culture of quality that ensures product safety, efficacy, and consumer trust.

Read More A Practical Guide to GMP Compliance for OTC Pharmaceutical Manufacturers
Inspections

FDA Pre-Approval Inspection Checklist: How to Prepare and What to Expect
ByFDA Inspections Team September 25, 2025September 25, 2025

The FDA Pre-Approval Inspection (PAI) is arguably the most critical regulatory milestone for any pharmaceutical company seeking to bring a new product to market. It’s not just another audit; it’s a comprehensive validation of your manufacturing process and a direct assessment of your readiness to produce a safe and effective drug. Failing a PAI can lead to significant delays and financial loss. This guide provides a definitive FDA pre-approval inspection checklist to help you prepare and succeed.

Read More FDA Pre-Approval Inspection Checklist: How to Prepare and What to Expect
Inspections

What to Expect in Virtual FDA Inspections for Dietary Supplement Facilitie
ByFDA Inspections Team September 25, 2025September 25, 2025

The FDA is increasingly using virtual inspections for dietary supplement facilities. This shift demands a new approach to compliance. Our in-depth guide explains what to expect from these Remote Regulatory Assessments (RRAs), how to prepare your technology and documentation, and strategies for navigating live-streamed tours and interviews. Learn how to maintain cGMP standards, avoid common pitfalls, and ensure your facility is ready for a seamless virtual audit from the FDA.

Read More What to Expect in Virtual FDA Inspections for Dietary Supplement Facilitie

FDA Inspections

Your trusted partner for FDA compliance and inspection readiness. With former ex-FDA’ers on our team, we provide the expertise and confidence you need to succeed.

Services

Industries

© 2024 FDA Inspections. All rights reserved.

THE IMMERSIVE FDA INSPECTION EXPERIENCE →

WARNING LETTERS 483 OBSERVATIONS